Purified equine rabies immune globulin: a safe and affordable alternative to human rabies immune globulin.

Abstract

Reported are the results of a retrospective study of 3156 patients who were treated at the Queen Saovabha Memorial Institute, Bangkok, with equine rabies immune globulin (ERIG). Only 51 patients (1.6%) exhibited serum-sickness-like reactions, none of which persisted for more than a week, and only 8 of these patients (15%) were treated with a short course of steroids. One patient, whose skin test was negative, had an immediate anaphylactic reaction to ERIG that responded to parenteral therapy with epinephrine and hydrocortisone sodium succinate. Serum-sickness-like reactions were more frequent among females and over 21-year-olds but were exceedingly rare (0.086%) among children under 10 years of age.

• Authors: H Wilde, P Chomchey, P Punyaratabandhu, P Phanupak, S Chutivongse
• Journal: Bulletin of the World Health Organization (Bull World Health Organ) Vol. 67 Issue 6 Pg. 731-6 ( 1989) ISSN: 0042-9686 [Print] Switzerland
• PMID: 2633888 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Rabies Vaccines

Topics

• Adolescent
• Adult
• Aged
• Anaphylaxis (etiology)
• Animals
• Child
• Female
• Horses (immunology)
• Humans
• Immunization, Passive (adverse effects)
• Male
• Middle Aged
• Rabies (therapy)
• Rabies Vaccines (adverse effects, therapeutic use)
• Rabies virus (immunology)
• Retrospective Studies
• Serum Sickness (etiology)